LGM Pharma has announced a $9 million expansion across its U.S. manufacturing network, marking the second phase of a broader contract development and manufacturing organization (CDMO) growth strategy. The latest investment builds on a previously disclosed $6 million upgrade in 2025, bringing the company’s total recent investment to $15 million as it seeks to strengthen domestic pharmaceutical manufacturing capacity.
The expansion will focus on facilities in Rosenberg, Texas, and Colorado Springs, Colorado, with the goal of increasing commercial-scale production, enhancing research and development (R&D) capabilities, and meeting growing demand for U.S.-based drug manufacturing.
In Rosenberg, LGM Pharma is allocating $4 million to expand manufacturing suites dedicated to suppositories, a dosage form experiencing rising demand, particularly in women’s health. The upgrades will also broaden the site’s R&D capabilities, enabling formulation and scale-up for a wider range of products, including solutions, suspensions, and semi-solid formulations. Importantly, the facility will remain fully operational during construction, ensuring uninterrupted supply to customers.
Meanwhile, the Colorado Springs site will receive a $5 million investment to boost capacity for niche, high-value oral solid dose (OSD) products. This includes orally disintegrating tablets (ODTs), an increasingly popular dosage form due to ease of administration and patient compliance. The facility has long served as LGM Pharma’s center of excellence for OSD development, and the expansion is expected to be completed within the year.
The move comes amid strong growth in the global OSD CDMO market, which was valued at more than $43 billion in 2024, with North America accounting for a significant share of manufacturing activity. LGM Pharma aims to capitalize on this demand by reinforcing its domestic footprint while maintaining its global sourcing capabilities.
Chief Executive Officer Prasad Raje said the investments reflect the company’s commitment to building a more resilient and integrated pharmaceutical supply chain. By combining U.S.-based drug product manufacturing with a global network of more than 220 pre-qualified active pharmaceutical ingredient (API) suppliers, the company offers end-to-end support across the full drug lifecycle—from development to commercialization.
The expansion follows the successful completion of Phase I upgrades at the Rosenberg facility, which included enhanced serialization systems and increased production capacity. Company executives emphasized that the phased approach allows LGM Pharma to scale operations incrementally while maintaining quality and minimizing disruption.
With demand for domestic manufacturing on the rise, LGM Pharma’s latest investment positions the company to better serve pharmaceutical firms developing branded and generic therapies, as well as those advancing regulatory pathways such as 505(b)(2), NDA, and ANDA programs.